Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine
Co-Administration of GSK Biologicals' Meningococcal Vaccine GSK134612 With Infanrix Hexa™, Compared to Individual Administration of Each Vaccine, in Healthy 12- Through 23-Month-Old Children
Sponsor: GlaxoSmithKline
A PHASE3 clinical study on Infections, Meningococcal, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 8 data snapshots since 2007. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Aug 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aschaffenburg, Germany , Athens, Greece , Bad Lobenstein, Germany , Bad Oeynhausen, Germany , Balve, Germany , Berlin, Germany , Bochum, Germany , Braunatal, Germany , Bretten, Germany , Bönnigheim, Germany and 66 more locations